Skip to the page

Data / Drug companies / Allergan, Inc.

Allergan, Inc.: 7 products in the FDA NDC directory, labeler code 58914

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Allergan, Inc. (labeler code 58914) lists 7 products in the FDA National Drug Code Directory, covering 4 finished drugs by generic name. By type: 6 prescription drugs, 1 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on June 21, 2011.

The request: Watch Allergan, Inc. (FDA labeler code 58914): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
58914
Products in commercial distribution
7
Packages
11
Finished drugs by generic name
4
Prescription products
6
Over the counter products
0
Flagged as original packager
5 of 5 products that carry the flag
Started marketing in the last 12 months
0
Products with a marketing end date set
1
Earliest marketing start
October 30, 1981
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)685.7%
Drugs for further processing114.3%

Products by type

TypeProductsShare
Prescription drugs685.7%
Drugs for further processing114.3%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Ursodiol228
Sucralfate239
Nitroglycerin140
Mesalamine141

Dosage forms

Dosage formProductsShare
Tablet, film coated228.6%
Tablet228.6%
Ointment114.3%
Suppository114.3%
Suspension114.3%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Rectiv58914-301OintmentNew drug applications (NDA)June 21, 2011
Canasa58914-501SuppositoryNew drug applications (NDA)January 5, 2001
Urso Forte58914-790Tablet, film coatedNew drug applications (NDA)December 10, 1997
Urso 25058914-785Tablet, film coatedNew drug applications (NDA)December 10, 1997
Carafate58914-170SuspensionNew drug applications (NDA)December 16, 1993
Sucralfate58914-172TabletDrugs for further processingOctober 30, 1981
Carafate58914-171TabletNew drug applications (NDA)October 30, 1981

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.